{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:58:51Z","timestamp":1793311131273,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Medical Radiation Sci"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anal canal cancer (ACC) is uncommon. The gold standard of care is chemoradiotherapy treatment. However, this treatment is associated with considerable acute and late side effects. The aim of this pilot study was to evaluate acute toxicity and patient\u2010reported outcomes (PRO) in these patients from planning to 3\u2009months after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixteen patients were recruited to this prospective observational study from March 2015 to December 2017. All patients received volumetric modulated arc therapy (VMAT) in 30#. Toxicity data were graded by a Radiation Oncologist using the Common Terminology Criteria for Adverse Effects (CTCAE) version 4 at planning, weekly during treatment, 6\u2010week and 3\u2010month post\u2010treatment. PRO data were collected using the EORTC QLQ C30 and CR29 questionnaires completed by patients at planning, mid and end treatment and 3\u2010month post\u2010treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority of toxicity and PRO items peaked in severity at the end of treatment (week 6). Skin was the only item where &gt;50% of patients had \u2265 grade 2 toxicity at any point with 75% having \u2265 grade 2 at week 6. Patient\u2010reported embarrassment significantly increased over time (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). No meaningful relationships were found between PRO and CTCAE results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After reaching their maximum severity at the end of treatment, the majority of toxicity and PRO items approached baseline levels by 3\u2010month post\u2010treatment. The results of this study suggest that PROs are an important complementary tool to CTCAE and provide greater understanding of patients' perception of treatment side effects.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmrs.604","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T10:45:23Z","timestamp":1656153923000},"page":"484-491","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute toxicity and patient\u2010reported outcomes in anal canal cancer: results of a pilot study"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-0578","authenticated-orcid":false,"given":"Elizabeth","family":"Brown","sequence":"first","affiliation":[{"name":"Radiation Oncology Princess Alexandra Hospital \u2013 Ipswich Road  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7576-7001","authenticated-orcid":false,"given":"Emma","family":"Le Cornu","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Alexandra Hospital \u2013 Ipswich Road  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Bui","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Alexandra Hospital \u2013 Ipswich Road  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bernard","sequence":"additional","affiliation":[{"name":"QCIF Bioinformatics, Institute for Molecular Bioscience University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Mai","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Alexandra Hospital \u2013 Ipswich Road  Brisbane Queensland Australia"},{"name":"School of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Harvey","sequence":"additional","affiliation":[{"name":"Radiation Oncology Princess Alexandra Hospital \u2013 Ipswich Road  Brisbane Queensland Australia"},{"name":"School of Medicine University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2012.08.011"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.04.013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31827e52a3"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.02.030"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.09.023"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.03.09"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21259"},{"key":"e_1_2_8_9_1","volume-title":"Guidance for Industry. Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"Administration USDoHaHSFaD","year":"2009"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1700-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.06.006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.12.058"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.07.006"},{"key":"e_1_2_8_14_1","unstructured":"Institute NC Common Terminology Criteria for Adverse Events (CTCAE) U.S. Department of Health and Human Services. Available from:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm.2021. Accessed 11th November 2021."},{"key":"e_1_2_8_15_1","unstructured":"Cancer EOftRaTo.Quality of Life questionnaires. EORTC. Available from:https:\/\/qol.eortc.org\/questionnaires\/.2022. Accessed 11th November 2021."},{"key":"e_1_2_8_16_1","volume-title":"R: A language and environment for statistical computing","year":"2020"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.06.020"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.06.061"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.12.004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3439"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr485"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3297-9"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.770599"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.11.018"}],"container-title":["Journal of Medical Radiation Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmrs.604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmrs.604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmrs.604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T20:45:25Z","timestamp":1692650725000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmrs.604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/jmrs.604"],"URL":"https:\/\/doi.org\/10.1002\/jmrs.604","archive":["Portico"],"relation":{},"ISSN":["2051-3895","2051-3909"],"issn-type":[{"value":"2051-3895","type":"print"},{"value":"2051-3909","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"2022-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}